11900894

Strauss JF 3rd

2002

Strategies to elucidate the mechanism of excessive theca cell androgen production in PCOS.

11910667

Norman RJ

1999

Polycystic ovary syndrome and implications for the menopause.

11913676

Ernst CL

2002

The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics.

11915581

Strowitzki T

2002

Body fat distribution, insulin sensitivity, ovarian dysfunction and serum lipoproteins in patients with polycystic ovary syndrome.

11915582

Kovacs GT

2002

Surgical or medical treatment of polycystic ovary syndrome: a cost-benefit analysis.

11925372

Homburg R

2002

Should patients with polycystic ovarian syndrome be treated with metformin? A note of cautious optimism.

11925403

Amer SA

2002

Laparoscopic ovarian diathermy in women with polycystic ovarian syndrome: a retrospective study on the influence of the amount of energy used on the outcome.

11925404

Nardo LG

2002

Three-dimensional assessment of ultrasound features in women with clomiphene citrate-resistant polycystic ovarian syndrome (PCOS): ovarian stromal volume does not correlate with biochemical indices.

11927624

Hogeveen KN

2002

Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction.

11928069

Vrb?kov? J

2002

Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome.

11930513

Goolsby MJ

2001

AACE hyperandrogenism guidelines.

11930528

Markle ME

2001

Polycystic ovary syndrome: implications for the advanced practice nurse in primary care.

11932281

Arslanian SA

2002

Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.

11932282

Jayagopal V

2002

The biological variation of insulin resistance in polycystic ovarian syndrome.

11932299

Ehrmann DA

2002

Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome.

11935324

Gu D

2002

Evidence of multiple causal sites affecting weight in the IGF2-INS-TH region of human chromosome 11.

11937112

Calvo RM

2002

Insulin gene variable number of tandem repeats regulatory polymorphism is not associated with hyperandrogenism in Spanish women.

11937113

Heard MJ

2002

Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome.

11937114

Zargar AH

2002

Epidemiologic and etiologic aspects of hirsutism in Kashmiri women in the Indian subcontinent.

11937150

Asada H

2002

Laparoscopic treatment of polycystic ovaries with the holmium:YAG laser.

11937153

Futterweit W

2002

Pre-analytical errors: everything that happens to the specimen up to the point of testing.

11937980

Laboureau-Soares Barbosa S

2002

[Polycystic ovary syndrome: treatment with insulin-sensitizing agents].

11942905

Douchi T

2002

Relationship of upper body obesity to menstrual disorders.

11951826

Gabrilove JL

2002

The pathogenesis of the polycystic ovary syndrome: a hypothesis.

11952033

Sheth RD

2002

Adolescent issues in epilepsy.

11953071

Song J

2002

[Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].

11955793

Rohr UD

2002

The impact of testosterone imbalance on depression and women's health.

11955795

Huber JC

2002

Genetic modeling of estrogen metabolism as a risk factor of hormone-dependent disorders.

11955796

Druckmann R

2002

IGF-1 in gynaecology and obstetrics: update 2002.

11960167

Chakravarty A

2002

Preliminary observations on valproate and cystic ovaries: letter to editor.

11960510

Rosenbloom AL

2002

Increasing incidence of type 2 diabetes in children and adolescents: treatment considerations.

11961383

Vrb?kov? J

2002

Prediction of the effect of metformin treatment in patients with polycystic ovary syndrome.

11964028

Kele?timur F

2001

Hirsutism of adrenal origin in adolescents: consequences in adults.

11964034

Macut D

2001

Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS).

11968579

Draveck? I

2002

[Hyperinsulinemia and disorders of the menstrual cycle].

11980739

Loh S

2002

The influence of body mass index, basal FSH and age on the response to gonadotrophin stimulation in non-polycystic ovarian syndrome patients.

11980740

Egbase PE

2002

'Early coasting' in patients with polycystic ovarian syndrome is consistent with good clinical outcome.

11981482

Fanchin R

2002

[LH Day: floodlights on a forgotten compound].

11981485

Chang RJ

2002

[Polycystic ovaries in 2001: physiology and treatment].

11984434

Tolstoi LG

2002

Weight Loss and Medication in Polycystic Ovary Syndrome Therapy.

11984435

McKittrick M

2002

Diet and Polycystic Ovary Syndrome.

11987018

Auernhammer CJ

2002

[Polycystic ovary syndrome and metabolic syndrome].

11987899

Hokken-Ko?lega AC

2002

Timing of puberty and fetal growth.

11994052

Sturrock ND

2002

Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice.

11994350

Charmandari E

2002

Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications.

11994352

Legro RS

2002

Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity.

11994353

Legro RS

2002

Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome.

12000206

O'Donovan C

2002

Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder.

12001601

Wijeyaratne CN

2002

Polycystic ovary syndrome and its relevance to women from south Asia.

12001778

Ma?ecka-Tendera E

2002

[Ovarian hyperandrogenism in adolescent girls with menstrual disorders].

12007900

Notelovitz M

2002

Androgen effects on bone and muscle.

12009344

Mastorakos G

2002

Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.

12009345

Morgan JF

2002

Polycystic ovarian morphology and bulimia nervosa: a 9-year follow-up study.

12009346

Telli MH

2002

Serum leptin levels in patients with polycystic ovary syndrome.

12009347

Fruzzetti F

2002

Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome.

12009371

Sindi O

2002

Diagnosis of simple endometrial hyperplasia in a woman with polycystic ovary syndrome with use of hysterosalpingography.

12009381

Cagnacci A

2002

A role for melatonin in PCOS?

12009391

Mitwally MF

2002

Troglitazone: a possible modulator of ovarian steroidogenesis.

12020974

Huber JC

2002

Genetic modelling of the estrogen metabolism as a risk factor of hormone-dependent disorders.

12030806

Stener-Victorin E

2001

Effects of electro-acupuncture on corticotropin-releasing factor in rats with experimentally-induced polycystic ovaries.

12032379

Seli E

2002

Optimizing ovulation induction in women with polycystic ovary syndrome.

12032385

Ledger W

2002

What to do about the polycystic ovary 'epidemic'.

12032389

Welt CK

2002

The physiology and pathophysiology of inhibin, activin and follistatin in female reproduction.

12032449

Legro RS

2002

Polycystic ovary syndrome. Long term sequelae and management.

12038887

Trent ME

2002

Quality of life in adolescent girls with polycystic ovary syndrome.

12039130

Adams Hillard PJ

2002

Menstruation in young girls: a clinical perspective.

12042261

Joseph-Horne R

2002

Luteal phase progesterone excretion in ovulatory women with polycystic ovaries.

12042287

Amer SA

2002

An evaluation of the inter-observer and intra-observer variability of the ultrasound diagnosis of polycystic ovaries.

12043351

Rutherford AJ

2002

The patient with recurrent miscarriage.

12044925

Norman RJ

2002

Hyperandrogenaemia and the ovary.

12050127

Seminara SB

2002

Genetic approaches to unraveling reproductive disorders: examples of bedside to bench research in the genomic era.

12050223

Haddad L

2002

Variation within the type 2 diabetes susceptibility gene calpain-10 and polycystic ovary syndrome.

12050266

Ib??ez L

2002

Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.

12050280

Gregory CW

2002

Steroid receptor coactivator expression throughout the menstrual cycle in normal and abnormal endometrium.

12053100

Loverro G

2002

The plasma homocysteine levels are increased in polycystic ovary syndrome.

12055331

Wang JX

2002

Obesity increases the risk of spontaneous abortion during infertility treatment.

12057535

Mulchahey KM

2002

In support of metformin use in adolescent polycystic ovary syndrome.

12057712

Ovalle F

2002

Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus.

12057716

Woods KS

2002

Effect of oral micronized progesterone on androgen levels in women with polycystic ovary syndrome.

12057717

Fulghesu AM

2002

N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome.

12057718

Ajossa S

2002

The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome.

12064892

Franks S

2002

Adult polycystic ovary syndrome begins in childhood.

12064893

White PC

2002

Long-term consequences of childhood-onset congenital adrenal hyperplasia.

12066790

Trent M

2002

Metformin in adolescents with polycystic ovary syndrome: opposed.

12070543

Malkawi HY

2002

The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome.

12078834

Wild RA

2002

Long-term health consequences of PCOS.

12078838

Olivennes F

2002

The use of GnRH antagonists in ovarian stimulation.

12079889

Vankov? M

2002

Association of insulin gene VNTR polymorphism with polycystic ovary syndrome.

12080440

Gambineri A

2002

Obesity and the polycystic ovary syndrome.

12082210

Lord J

2002

Polycystic ovary syndrome and fat distribution: the central issue?

12087022

Vrb?kov? J

2002

Insulin sensitivity and beta-cell function in women with polycystic ovary syndrome.

12087495

Brannian JD

2002

Leptin and ovarian folliculogenesis: implications for ovulation induction and ART outcomes.

12089937

Pugeat M

2000

[Genetics of the polycystic ovarian syndrome and therapeutic perspectives ].

12093242

Kirpichnikov D

2002

Metformin: an update.

12093774

Lakhani K

2002

Impaired carotid viscoelastic properties in women with polycystic ovaries.

12093831

Elter K

2002

Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.

12093932

Rimsza ME

2002

Dysfunctional uterine bleeding.

12095490

Legro RS

2002

Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated.

12095507

Greisen S

2002

Regulation of insulin-like growth factor binding protein secretion by human granulosa luteal cells in a polycystic ovary-like environment.

12098657

Abbott DH

2002

Developmental origin of polycystic ovary syndrome - a hypothesis.